The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
|Articles|July 31, 1996
FDA panel recommends ProstaScint MoAb
A Food and Drug Administration advisory committee last week votedunanimously to recommend that the agency approve Cytogen's productlicense application for ProstaScint, a monoclonal antibody-basedimaging agent for detecting prostate cancer. The FDA's
Advertisement
A Food and Drug Administration advisory committee last week votedunanimously to recommend that the agency approve Cytogen's productlicense application for ProstaScint, a monoclonal antibody-basedimaging agent for detecting prostate cancer. The FDA's MedicalImaging Drug Advisory Committee recommended approval for usingProstaScint in patients with prostate cancer in whom there isa high clinical suspicion of occult metastatic disease. The paneladvised that the information provided by ProstaScint be used withother diagnostic information.
Cytogen, of Princeton, NJ, is hoping that ProstaScint willexperience greater commercial success than OncoScint CR/OV, amonoclonal antibody-based agent for detecting colorectal and ovariancancer. OncoScint was launched in 1993 but has experienced slowsales since then. Cytogen believes the market potential for ProstaScintis larger than that of OncoScint: The American Cancer Societyestimates that there will be 317,000 new cases of prostate cancerin the U.S. in 1996, and 41,000 deaths from the disease.
Cytogen is looking for a marketing partner for ProstaScint,and is particularly interested in a company with experience inurology, as urologists are the physicians who will order ProstaScintscans.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
SubscribeAdvertisement
Related to this article
Expert Radiology is a **radiologist-run teleradiology practice with 10 years of experience**, hiring teleradiologists earning **$500–$900/hr with per-dictation pay**. Work from anywhere with true flexibility, **no shifts, no call, and no weekends**.
Our case mix is **predominantly outpatient and noncontrast**, with approximately **75% MRI**, plus X-ray and CT.
We cover **malpractice with tail**, handle all medical licensing, and ship you a **$10K reading station with six vertical 4K monitors**.
Minimum commitment is an **average of 400 cases per month**.
**Book a call with Brandi Escapule, Principal, Physician Services.**
How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.
While the allure of partnership or a hierarchical promotion system for those who paid their dues once sounded promising, the current reality amid declining reimbursements, thinning practice margins and private equity acquisitions is going after the gig with the most optimal lifestyle and paycheck.
Catch up on the top radiology content of the past week.
In the third of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss recent developments with autonomous AI in breast imaging and share their perspective on the overall potential of AI to help mitigate the radiologist shortage.
In a recent interview, Amir Iravani, MD, FRACP, discussed the radiotherapeutic agent 177Lu-edotreotide and new dosimetry data from the COMPETE trial that was recently presented at the ASTRO conference.
While AI offers the lure of efficiency and cleaner writing in scientific research, maintaining the principles of authorship and intellectual engagement is perhaps more important than ever before.
Advertisement
Advertisement